New data recently presented at the 2015 American College of Rheumatology Annual Meeting in San Francisco showed that mycophenolate mofitil is as efficient as cyclophosphamide for the treatment of interstitial lung disease in individuals with scleroderma. Scleroderma, or systemic sclerosis, is a chronic systemic autoimmune disease characterized by a…
Researchers at St. Elizabeth’s Medical Center in Stow, Massachusetts, recently reported a clinical case of pulmonary lymphoma in a patient diagnosed with scleroderma. The data was presented at the American College of Chest Physicians Annual Meeting (CHEST 2015), held Oct. 24–28 in Montreal, Canada, under the title “…
iBio, Inc., a plant-based biotechnology company focused on developing biological therapies for several fibrotic diseases including idiopathic pulmonary fibrosis and systemic sclerosis, recently announced it has received a notification from the European Patent Office stating that the opposition period for the iBio patent 2192172, entitled “System for Expression of…
Reata Pharmaceuticals, Inc., a biopharmaceutical company based in Irving, Texas, recently announced positive data from the Phase 2 clinical trial LARIAT assessing the company’s candidate product bardoxolone methyl for pulmonary arterial hypertension (PAH). The results were recently presented by Dr. Ronald Oudiz, Director of the Pulmonary Hypertension Center and…
Cytori Therapeutics, Inc., a company focused on therapeutics and devices in the field of regenerative medicine, recently reported it has enrolled and administered treatment to the first patient in its ongoing SCLERADEC-II trial, a late phase, follow-on European study that aims to evaluate the efficacy and safety profile of Cytori…
A new study recently published in the journal BMC Musculoskeletal Disorders revealed that patients with systemic sclerosis have a reduced incidence of Crohn’s disease in comparison to the general population. The study was performed by a team of researchers at several universities in Taiwan, and is entitled…
In a recent study published in the journal Arthritis & Rheumatology, entitled, “Pulmonary Function Tests: High Rate of False Negatives in the Early Detection and Screening of Scleroderma Interstitial Lung Disease,” a team of researchers from the University Hospital Zurich led by…
Late stage cell therapy developer Cytori Therapeutics, a company creating autologous cell therapies from adipose tissue to treat a variety of medical conditions, recently published its findings from a 12-month clinical follow-up of scleroderma patients who were enrolled in the Scleradec-I clinical trial on hand dysfunction associated with the disease. The Scleradec-I study, an…
Corbus Pharmaceuticals Holdings, Inc. a clinical stage drug development company targeting chronic, rare, and serious inflammatory and fibrotic diseases with clear unmet needs, recently announced the initiation of patient enrollment for its Phase 2 trial of Resunab™ for the treatment of diffuse cutaneous systemic sclerosis. Systemic Sclerosis (Scleroderma) is a…
A new study recently published in the journal Arthritis Research & Therapy provides encouraging data on a pilot study evaluating nilotinib (Tasigna™) as a therapy for diffuse systemic sclerosis. The study is entitled “Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis:…
Get regular updates to your inbox.